View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports

Genexine Inc: 1 director

A director at Genexine Inc bought 5,000 shares at 7,710.000KRW and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearl...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Int'l Compass: Global Equity Strategy

Stay Defensive With Technology, Health Care, Staples Upside momentum continues to wane for global equities, a trend we mentioned in last week's Int'l Compass. In that report we highlighted early signs of lower highs forming in the major global indexes. Price action this week has indeed confirmed lower highs for now in the MSCI ACWI, ACWI ex-US, EAFE, and EM indexes. These lower highs increase the probability for breakdowns and a deeper pullback, but we do not want to get ahead of ourselves. Unt...

 PRESS RELEASE

Genexine Receives Approval to Initiate Phase Ib/II Trial of GX-188E, H...

SEONGNAM, South Korea--(BUSINESS WIRE)-- Genexine Inc. (KOSDAQ: 095700), a clinical stage biotechnology company developing innovative biologics focused on immuno-oncology and orphan diseases, announced that the Ministry of Food and Drug Safety (MFDS) in Korea has granted approval to initiate a Phase Ib/II trial of GX-188E, an HPV therapeutic DNA vaccine, in combination with KEYTRUDA® (pembrolizumab), an anti-PD-1 therapy marketed by Merck & Co., Inc., Kenilworth, NJ, USA (known as MSD outside the United States and Canada), for ...

 PRESS RELEASE

Genexine Releases Positive Interim Phase 2 Clinical Data from PGHD Tri...

ORLANDO, Fla.--(BUSINESS WIRE)-- Genexine Inc. (KOSDAQ: 095700) and Handok Inc. (KRX: 002390), co-developing next-generation, long-acting recombinant human growth hormone (rhGH), consisting Genexine’s proprietary hybrid Fc (hyFc) platform technology for pediatric and adult growth hormone deficiency (GHD) patients called GX-H9, today presented positive interim results from the ongoing phase 2 clinical trials of GX-H9 in pediatric growth hormone deficiency and full data from adult growth hormone deficiency (GHD) at the 99t...

 PRESS RELEASE

Genexine to Present at the 35th J.P. Morgan Healthcare Conference

SEONGNAM, South Korea--(BUSINESS WIRE)-- Genexine Inc. (KOSDAQ: 095700), a clinical stage biotechnology company developing innovative biologics focused on immuno-oncology and metabolic/autoimmune diseases, today announced that Dr. H. Michael Keyoung, CEO and President of Genexine, will present at the J.P. Morgan 35th Annual Healthcare Conference Emerging Markets Track on January 11th at the Westin St. Francis Hotel, San Francisco. The J.P. Morgan Healthcare Conference is one of the healthcare industry’s biggest events of the ye...

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind...

 PRESS RELEASE

Genexine Enters into Clinical Research Collaboration with MSD

SEONGNAM, South Korea--(BUSINESS WIRE)-- Genexine (KOSDAQ:095700), a clinical stage biotechnology company developing innovative biologics, today announced that it has entered into a clinical research collaboration with Merck & Co., Inc. (NYSE:MRK), Kenilworth, NJ, USA (known as MSD outside the US and Canada), for the assessment of Genexine’s GX-188E, HPV therapeutic DNA vaccine, in combination with MSD’s anti-PD-1 therapy, Keytruda® (pembrolizumab), for the treatment of patients with HPV-induced cancers. Under t...

 PRESS RELEASE

Genexine Granted FDA Orphan Drug Designation for GX-H9 in Growth Hormo...

SEONGNAM, South Korea--(BUSINESS WIRE)-- Genexine (KOSDAQ: 095700), an innovative biotechnology company focused on immuno-oncology, metabolic and orphan diseases, announced today that US FDA Office of Orphan Products Development (OOPD) has granted GX-H9 an orphan drug designation for the treatment of growth hormone deficiency. GX-H9 is next-generation, long-acting recombinant human growth hormone (rhGH) consisting of recombinant growth hormone genetically fused to Genexine’s proprietary hybrid Fc (hyFc) platform...

New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch